Bernstein lowered the firm’s price target on BeiGene to $161 from $196 and keeps a Market Perform rating on the shares. The analyst updated the company’s model to reflect the latest earnings results, changes in pipeline assets, and commercial updates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
